scholarly journals Investigation of the effectiveness of the drug «Glenspray active» in patients with allergic rhinitis

2019 ◽  
pp. 49-53
Author(s):  
Vladimir Bereznyuk ◽  
Alexander Chernokur
Keyword(s):  
Allergic Rhinitis ◽  
Epidemiological Studies ◽  
Nasal Symptom ◽  
Maximum Effect ◽  
Symptom Scale ◽  
The Past ◽  
Nasal Symptoms ◽  
Total Nasal Symptom Score ◽  
Number Of Patients ◽  
Effect Of Therapy

Relevance: Over the past decade, an increase in the number of patients with AR has been noted. According to epidemiological studies conducted in different countries, the prevalence of AR is from 1 to 40%. In most European countries, 10-25% of the population suffers from allergic rhinitis. Of particular interest for treatment are combination preparations containing topical corticosteroids and antihistamines, in particular, Glenspray Active. The active ingredients of the drug are mometasone furoate and azelastine hydrochloride. The purpose: study of effectiveness of the drug «Glenspray Active» usage in patients with allergic rhinitis. Results and discussion: 69 patients with allergic rhinitis were treated in the clinic of the SE «DMA of HM of Ukraine». In 61 patients intermittent AR was diagnosed, in 8 patients - persistent AR. Efficiency criteria were an assessment of the effect of therapy with the studied drug on the nasal symptoms of allergic rhinitis. To analyze the indicators, a general nasal symptom scale (TNSS – Total Nasal Symptom Score) was used, and the overall effectiveness of treatment by the patient and the research doctor was also evaluated. Most of patients (49-57%) noted a good and excellent effect from the use of the drug which occurred already between 30 and 60 minutes after the start of treatment. 85.5% of patients noted the maximum effect of the using of the drug which was between 30 and 60 minutes. Conclusion: The combined drug «Glenspray Active» is an effective and safe tool in the treatment of patients with AR. A good and excellent clinical effect in the form of a significant reduction in nasal symptoms (TNSS) occurs from 30 to 60 minutes in 44-57% of patients. The maximum effect from the use of the drug was observed between 30 and 60 minutes in 85.5% of patients.

scholarly journals Efektivitas salin hipertonik terhadap waktu transpor mukosiliar dan skor gejala hidung penderita rinitis alergi

2018 ◽  
Vol 47 (2) ◽  
pp. 123
Author(s):  
Woro Safitri ◽  
Dwi Reno Pawarti ◽  
Titiek Hidayati Ahadiah
Keyword(s):  
Clinical Trial ◽  
Allergic Rhinitis ◽  
Symptom Score ◽  
Saline Group ◽  
Nasal Symptom ◽  
Control Group ◽  
Mucociliary Transport ◽  
Transport Time ◽  
Total Nasal Symptom Score ◽  
The Mean

Latar belakang: Rinitis alergi (RA) adalah suatu penyakit inflamasi mukosa hidung yang diperantara oleh imunoglobulin E (IgE), setelah mukosa hidung terpapar alergen. Tujuan: Mengidentifikasi efektivitas cuci hidung salin hipertonik terhadap waktu transpor mukosiliar dan skor gejala hidung total (SGHT) pada penderita RA. Metode: Penelitian dilaksanakan pada bulan Juli hingga Desember 2016 di Poli Telinga Hidung Tenggorok – Bedah Kepala Leher Rumah Sakit Dr. Soetomo Surabaya. Uji klinis acak terkontrol pada 2 kelompok dengan desain control group in clinical trial. Pengambilan sampel dilakukan secara consecutive sampling. Uji korelasi yang digunakan adalah uji t berpasangan dan uji Wilcoxon. Hasil: Didapatkan sampel 42 penderita, yaitu 21 penderita pada kelompok loratadin, serta 21 penderita pada kelompok loratadin dan cuci hidung salin hipertonik. Didapatkan rerata penurunan transpor mukosiliar kelompok loratadin dan cuci hidung salin hipertonik lebih bermakna daripada kelompok loratadin (p=0,001). Penurunan transpor mukosiliar kelompok loratadin didapatkan rerata -2,30 (SD=2,77), kelompok loratadin dan cuci hidung salin hipertonik didapatkan rerata -6,27 (SD=3,91). Penurunan SGHT kelompok loratadin didapatkan rerata -2,48 (SD=1,72), sedangkan kelompok loratadin dan cuci hidung salin hipertonik didapatkan rerata -4,3 (SD=1,20). Kesimpulan: Penambahan cuci hidung salin hipertonik pada terapi loratadin lebih efektif dibandingkan terapi tunggal loratadin dalam menurunkan transpor mukosiliar dan SGHT pada penderita RA. Kata kunci: Loratadin, cuci hidung salin hipertonik, transpor mukosiliar, skor gejala hidung total, rinitis alergi ABSTRACT Background: Allergic rhinitis (AR) is a nasal mucous membrane inflamatory which mediated by Imunoglobulin E (IgE) after allergen exposure in nasal mucosa. Purpose: To identify the effectiveness of nasal hypertonic saline irrigation on reduction of mucociliary transport time (MCTT) and total nasal symptom score (TNSS) in AR patients. Methods: The was conducted from July until December 2016 in Oto Rhino Laryngology - Head and Neck Surgery of Dr. Soetomo Hospital Surabaya. The study was randomized controlled clinical trials on two groups, with the control group in clinical trial design. Paired t and Wilcoxon test was used as the correlation test. Results: There was 42 patients, 21 patients in loratadine group, and 21 patients in loratadine with hypertonic nasal saline group. The average of mucociliary transport time decrease of loratadine with hypertonic nasal saline group was more significant than loratadine group (p=0.001). The mean of decreasing mucociliary transport time in loratadine group was -2.30 (SD=2.77) and loratadine with hypertonic nasal saline group was -6.27 (SD=3.91). The mean of decreasing TNSS in loratadin group was -2.48 (SD=1.72), and loratadin with hypertonic nasal saline group was -4.3 (SD=1.20). Conclusions: The addition of hypertonic nasal saline in loratadine was more effective, compared to monotherapy of loratadine in decreasing mucociliary transport time and TNSS in patient with AR. Keywords: Loratadine, hypertonic nasal saline, mucociliary transport, total nasal symptom score, allergic rhinitis

Bisphenol A as a risk factor for allergic rhinitis in children

2020 ◽  
pp. 096032712095810
Author(s):  
A Nalbantoğlu ◽  
A Çelikkol ◽  
N Samancı ◽  
NC Günaydın ◽  
B Nalbantoğlu
Keyword(s):  
Allergic Rhinitis ◽  
Bisphenol A ◽  
Disease Severity ◽  
Allergic Diseases ◽  
Nasal Symptom ◽  
Interleukin 4 ◽  
Control Group ◽  
Healthy Children ◽  
Endocrine Disrupting Compound ◽  
Total Nasal Symptom Score

Aim: Bisphenol-A (BPA) is an endocrine disrupting compound and may exacerbate or induce allergic diseases. To the best of our knowledge, there is little evidence regarding the effects of BPA exposure on allergic rhinitis (AR) in children. In the present study, we sought to examine whether exposure to BPA in children is associated with AR. Methods: This study was designed as a case controlled clinical study. 140 children diagnosed as allergic rhinitis and 140 healthy children as control group were recruited. BPA, interleukin-4, interleukin-13, total IgE and interferon-gamma levels were determined. Skin prick tests were performed in patient group. Total nasal symptom score and ARIA classification were used to predict disease severity. Results: Serum IL-4, IgE and BPA levels of children with allergic rhinitis were found to be significantly higher than the control group. BPA and IL-4 levels were significantly higher in moderate to severe-persistent group. There was a positive correlation between total nasal symptom scores and Bisphenol A levels in children with allergic rhinitis. Conclusions: The present study is the first to observe statistically significant relationship between BPA concentrations and allergic rhinitis in children. Also increased levels of BPA are associated with disease severity.

scholarly journals Acupuncture Treatment of a Patient with Persistent Allergic Rhinitis Complicated by Rhinosinusitis and Asthma

2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
Ae-Ran Kim ◽  
Jun-Yong Choi ◽  
Jong-In Kim ◽  
So-Young Jung ◽  
Sun-Mi Choi
Keyword(s):  
Allergic Rhinitis ◽  
Clinical Studies ◽  
Symptom Relief ◽  
Nasal Symptom ◽  
Forced Expiratory Volume ◽  
Life Questionnaire ◽  
Total Nasal Symptom Score ◽  
Persistent Allergic Rhinitis ◽  
Significant Clinical Improvement ◽  
The Face

A pathophysiologic relationship between allergic rhinitis and rhinosinusitis and asthma has long been suggested. However, few clinical studies of acupuncture have been conducted on these comorbid conditions. A 48-year-old male suffering from persistent allergic rhinitis with comorbid chronic rhinosinusitis and asthma since the age of 18 years was studied. He complained of nasal obstruction, sneezing, cough, rhinorrhea and moderate dyspnea. He occasionally visited local ear-nose-throat clinics for his nasal symptoms, but gained only periodic symptom relief. The patient was treated with acupuncture, infrared radiation to the face and electro-acupuncture. Needles were inserted at bilateral LI20, GV23, LI4 and EX-1 sites with De-qi. Electro-acupuncture was performed simultaneously at both LI20 sites and additional traditional Korean acupuncture treatments were performed. Each session lasted for 10 min and the sessions were carried out twice a week for 5 weeks. The patient’s Mini-Rhinoconjunctivitis Quality-of-Life Questionnaire score decreased from 38, at the beginning of treatment, to 23, 3 weeks after the last treatment. The Total Nasal Symptom Score was reduced from six (baseline) to five, 3 weeks after the last treatment. There was significant clinical improvement in the forced expiratory volume in 1 s—from 3.01 to 3.50 l—with discontinuation of the inhaled corticosteroid, and no asthma-related complaints were reported. Further clinical studies investigating the effectiveness of acupuncture for the patients suffering from allergic rhinitis and/or rhinosinusitis with comorbid asthma are needed.

Airway Nitric Oxide in Children with HDM-Induced Allergic Rhinitis

2021 ◽  
pp. 194589242110644
Author(s):  
Woralak Sutiratanachai ◽  
Watcharoot Kanchongkittiphon ◽  
Natchanun Klangkalya ◽  
Wanlapa Jotikasthira ◽  
Potjanee Kiewngam ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Allergic Rhinitis ◽  
Provocation Test ◽  
Specific Ige ◽  
Nasal Symptom ◽  
Roc Curve Analysis ◽  
Prick Test ◽  
Vas Score ◽  
Total Nasal Symptom Score ◽  
Wheal Diameter

Background Rhinitis is a common problem in children. Airway nitric oxide (NO) was proposed to represent eosinophilic inflammation. Objectives To evaluate airway NO level in children with house dust mite (HDM)-induced allergic rhinitis Methods Children aged 5 to 18 years old with moderate–severe persistent rhinitis and positive result for the HDM nasal provocation test (NPT) was enrolled. The nasal symptoms evaluated by total nasal symptom score (TNSS) and visual analog scale (VAS) were recorded. Skin prick test (SPT) to common aeroallergens, fractional exhaled nitric oxide (FeNO), nasal nitric oxide (nNO), and blood test for specific IgE (sIgE) to HDM was measured. Rhinitis severity was categorized as severe if the VAS score > 7. Results Forty-eight children with HDM-induced allergic rhinitis with the mean age of 9.3 ± 2.4 years were enrolled. nNO levels and VAS score were significantly correlated (R = 0.398, P = .005). Children with severe rhinitis had significantly higher nNO levels than moderate rhinitis (1652.05 vs 941.30 parts per billion [ppb], P = .002), while there was no difference in FeNO level. ROC curve analysis demonstrated the cut-off value of nNO at 1350 ppb (AUC 0.764, 95% CI: 0.616-0.911, P = .002) for detecting severe HDM-induced allergic rhinitis with the sensitivity of 78% and the specificity of 71%. The level of FeNO in children who had HDM mean wheal diameter (MWD) > 8 mm was significantly higher than those with HDM MWD of 3 to 8 mm and those with a negative test (39.7 vs 14.3 vs 14.4 ppb; P = .006, respectively). Children who had sIgE to HDM < 0.35 KUA/L had significantly lower FeNO than those with sIgE to HDM 0.35 to 50 KUA/L and >50 KUA/L (9.5 vs 19.7 vs 40.4 ppb; P = .029, respectively). Conclusions Cut-off value for the diagnosis of severe HDM-induced chronic rhinitis was proposed. Rhinitis children who had a higher degree of HDM sensitization had a higher level of FeNO.

scholarly journals Efficacy of Mometasone Furoate and Fluticasone Furoate on Persistent Allergic Rhinoconjunctivitis

2013 ◽  
Vol 4 (3) ◽  
pp. ar.2013.4.0065 ◽  
Author(s):  
W. Hamizan Aneeza ◽  
Salina Husain ◽  
Roslenda Abdul Rahman ◽  
Dexter Van Dort ◽  
Asma Abdullah ◽  
...  
Keyword(s):  
Symptom Score ◽  
Nasal Symptom ◽  
Allergic Rhinoconjunctivitis ◽  
Mometasone Furoate ◽  
Fluticasone Furoate ◽  
Ocular Symptoms ◽  
Nasal Symptoms ◽  
Total Nasal Symptom Score ◽  
Significant Difference ◽  
Symptom Scores

Allergic rhinoconjunctivitis denotes both nasal and ocular manifestation of allergy, which may be solely treated with intranasal steroid. This study compares the efficacy of mometasone furoate nasal spray (NS) and fluticasone furoate NS in treatment of allergic rhinoconjunctivitis. The secondary objective is to study the severity of baseline ocular symptoms in allergic rhinoconjunctivitis. Seventy-eight patients with allergic rhinoconjunctivitis were assessed subjectively and objectively using twice-daily symptom scores for nasal (reflective total nasal symptom score [rTNSS] and instantaneous TNSS [iTNSS]) and ocular (reflective total ocular symptom score [rTOSS] and instantaneous TOSS [iTOSS]) symptoms, rhinoconjunctivitis quality-of-life questionnaires (RQOLQs), and acoustic rhinometry. All measurements were taken at baseline and at 4 and 8 weeks of treatment. Sixty-three patients who were randomized into the mometasone furoate group (n = 36) and the fluticasone furoate group (n = 27) completed the study. Seventy-six percent of patients had mild ocular symptoms, 20.5% had moderate symptoms, and only 2.6% had severe symptoms at baseline based on the iTOSS; 65.1% had mild nasal symptoms and 3% had severe nasal symptoms. There was significant reduction in the symptom scores after 1 week (p < 0.05). Both groups had significant improvement in RQOLQ scores after 1 month, which further improved at 2 months (p < 0.05). The nasal dimensions also improved in both groups (p < 0.05) but there was no statistically significant difference between groups. Both mometasone furoate and fluticasone furoate are effective as single-modality treatment of allergic rhinoconjunctivitis. The majority of patients manifest mild ocular symptoms that may be solely treated with intranasal steroids.

The association between the reflux symptoms index and nasal symptoms among patients with non-allergic rhinitis

2021 ◽  
pp. 1-5
Author(s):  
A W Hamizan ◽  
Y Y Choo ◽  
P V Loh ◽  
N F Abd Talib ◽  
M F Mohd Ramli ◽  
...  
Keyword(s):  
Allergic Rhinitis ◽  
Laryngopharyngeal Reflux ◽  
Nasal Symptom ◽  
Reflux Symptom ◽  
Reflux Symptom Index ◽  
Symptom Index ◽  
Cross Sectional ◽  
Nasal Symptoms ◽  
Reflux Symptoms ◽  
Non Allergic Rhinitis

Abstract Background Laryngopharyngeal reflux symptoms assessed with the reflux symptom index can overlap with non-allergic rhinitis symptoms. This study aims to explore the association between the reflux symptom index and nasal symptoms in non-allergic rhinitis patients. Methods A cross-sectional study was conducted on consecutive adults with non-allergic rhinitis. The reflux symptom index (score of more than 13 = laryngopharyngeal reflux) and nasal symptoms (categorised as mild (total score of 0–3), moderate (4–7) or severe (8–12)) were assessed. Results The study included 227 participants (aged 58.64 ± 12.39 years, 59.5 per cent female). The reflux symptom index scores increased with total nasal symptom scores (mild vs moderate vs severe, 8.61 ± 6.27 vs 12.94 ± 7.4 vs 16.40 ± 8.10; p < 0.01). Logistic regression indicated that laryngopharyngeal reflux is more likely in patients with severe nose block (odds ratio 5.47 (95 per cent confidence interval = 2.16–13.87); p < 0.01). Conclusion Laryngopharyngeal reflux symptoms are associated with nasal symptom severity, and nasal symptoms should be primarily treated. Those with predominant nose block and laryngopharyngeal reflux symptoms are more likely to have laryngopharyngeal reflux.

A randomized study comparing the efficacy of mometasone furoate and fluticasone furoate on the ocular and nasal symptoms of allergic rhinitis

2017 ◽  
Vol 3 (4) ◽  
pp. 918
Author(s):  
Satvinder Singh Bakshi ◽  
Surianarayanan Gopalakrishnan ◽  
Nirmal Coumare V.
Keyword(s):  
Allergic Rhinitis ◽  
Symptom Score ◽  
Nasal Spray ◽  
Randomized Study ◽  
Nasal Symptom ◽  
Mometasone Furoate ◽  
Fluticasone Furoate ◽  
Ocular Symptoms ◽  
Nasal Symptoms ◽  
Group B

<p class="abstract"><strong>Background:</strong> Ocular symptoms like itching, redness and congestion are common in patients with allergic rhinitis. These symptoms affect the quality of life and increase the burden on the healthcare cost. Intranasal steroids are effective in reducing the nasal and ocular symptoms of allergic rhinitis. We aim to compare the efficacy of mometasone furoate nasal spray and fluticasone furoate nasal spray in reducing the nasal and ocular symptoms of allergic rhinitis.</p><p class="abstract"><strong>Methods:</strong> 90 patients with perennial allergic rhinitis and ocular symptoms were randomly divided into 2 groups. Group A (n=46) received 200 µg of mometasone furoate nasal spray once daily and Group B (n=44) received 110 µg of fluticasone furoate nasal spray daily. The patients were assessed by total ocular symptom score [TOSS] and total nasal symptom score [TNSS] at 2, 6 and 12 weeks interval.  </p><p class="abstract"><strong>Results:</strong> There was a statistically significant reduction in both the groups in respect to the TOSS and TNSS scores. However the improvement in the TOSS score in the fluticasone furoate group was more than the mometasone furoate group by 6 weeks (p=0.0009), which continued till the 12 weeks (p=0.045).</p><p><strong>Conclusions:</strong> Fluticasone furoate is more effective than mometasone furoate in managing the ocular and nasal symptoms of allergic rhinitis. </p>

Sign in / Sign up

Export Citation Format

Share Document